Literature DB >> 7389518

Transanal advancement of the anterior rectal wall for vaginal fistulas involving the lower rectum.

J R Hilsabeck.   

Abstract

Experience from a personal series of nine patients with anovaginal or low rectovaginal fistula, operated upon by what is known as the Noble-Elting-Laird technique, is presented and added to the literature concerning the subject. Extensive preoperative mechanical bowel preparation including antibiotics was unnecessary as was a diverting colostomy. There were no operative deaths. Fistula did not recur in any of the nine patients followed six months, nor in any of eight of the nine patients followed over a period of two to 20 years. On comparing patients with anovaginal and rectovaginal fistula treated by transanal advancement of the anterior rectal wall with those patients treated by local layer closure, vaginally or anally, transanal advancement of the anterior rectal wall seems to be the better choice, particularly for the patient with a recurrent fistula. The data support the thesis that, since the anorectum is the primary source of such vaginal fistulas, the condition is best approached and treated accordingly.

Entities:  

Mesh:

Year:  1980        PMID: 7389518     DOI: 10.1007/bf02587089

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

1.  Obstetric and cryptoglandular rectovaginal fistulas: long-term surgical outcome; quality of life; and sexual function.

Authors:  Galal El-Gazzaz; Tracy L Hull; Emilio Mignanelli; Jeffery Hammel; Brooke Gurland; Massarat Zutshi
Journal:  J Gastrointest Surg       Date:  2010-07-01       Impact factor: 3.452

2.  Why do we have so much trouble treating anal fistula?

Authors:  Haig Dudukgian; Herand Abcarian
Journal:  World J Gastroenterol       Date:  2011-07-28       Impact factor: 5.742

3.  Transvaginal approach for repair of rectovaginal fistulae complicating Crohn's disease.

Authors:  J J Bauer; M E Sher; H Jaffin; D Present; I Gelerent
Journal:  Ann Surg       Date:  1991-02       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.